Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial.
about
Evidence-based recommendations on androgen deprivation therapy for localized and advanced prostate cancerEvolving Paradigm of Radiotherapy for High-Risk Prostate Cancer: Current Consensus and Continuing ControversiesMechanistic Insights into Molecular Targeting and Combined Modality Therapy for Aggressive, Localized Prostate CancerContemporary Management of Prostate CancerOptimal duration of androgen deprivation therapy following radiation therapy in intermediate- or high-risk nonmetastatic prostate cancer: A systematic review and metaanalysisOptimal management of prostate cancer with lethal biology--state-of-the-art local therapyPatient-reported outcomes in randomised controlled trials of prostate cancer: methodological quality and impact on clinical decision makingAltering the response to radiation: sensitizers and protectorsProstate radiotherapy for men with metastatic disease: a new comparison in the Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE) trialA comprehensive review of contemporary role of local treatment of the primary tumor and/or the metastases in metastatic prostate cancerProstate cancer: ESMO Consensus Conference Guidelines 2012A Randomized Control Trial Comparing the Efficacy of Antiandrogen Monotherapy: Flutamide vs. BicalutamideEfficacy and Safety of Combined Androgen Deprivation Therapy (ADT) and Docetaxel Compared with ADT Alone for Metastatic Hormone-Naive Prostate Cancer: A Systematic Review and Meta-AnalysisCelecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial.Failure-Free Survival and Radiotherapy in Patients With Newly Diagnosed Nonmetastatic Prostate Cancer: Data From Patients in the Control Arm of the STAMPEDE Trial.What is the quality of economic evaluations of non-drug therapies? A systematic review and critical appraisal of economic evaluations of radiotherapy for cancer.Recommended patient-reported core set of symptoms to measure in prostate cancer treatment trials.(18)F-FDG-PET/CT and (18)F-NaF-PET/CT in men with castrate-resistant prostate cancer.Effectiveness of androgen-deprivation therapy and radiotherapy for older men with locally advanced prostate cancer.Trends and outcome from radical therapy for primary non-metastatic prostate cancer in a UK population.Cooperative Group Cancer Clinical Trials: An NCIC Clinical Trials Group Perspective.The impact of increasing dose on overall survival in prostate cancer.Bias in estimating the causal hazard ratio when using two-stage instrumental variable methods.Final Report of the Intergroup Randomized Study of Combined Androgen-Deprivation Therapy Plus Radiotherapy Versus Androgen-Deprivation Therapy Alone in Locally Advanced Prostate CancerImpact of Radiotherapy When Added to Androgen-Deprivation Therapy for Locally Advanced Prostate Cancer: Long-Term Quality-of-Life Outcomes From the NCIC CTG PR3/MRC PR07 Randomized Trial.Impact of the duration of hormonal therapy following radiotherapy for localized prostate cancer.High-risk prostate cancer-classification and therapy.Treatment of localized prostate cancer in elderly patients.The Globalization of Cooperative Groups.An examination of prostate cancer trends in Australia, England, Canada and USA: Is the Australian death rate too high?Radiation therapy to the primary tumor in locally advanced prostate cancer is not "closing the barn door after the horse has bolted".Favorable outcomes in locally advanced and node positive prostate cancer patients treated with combined pelvic IMRT and androgen deprivation therapyFlexible trial design in practice - stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial.The management of high-risk, locally advanced, prostate cancer radiation therapyFeasibility, acceptability, and preliminary efficacy of a technology-assisted psychosocial intervention for racially diverse men with advanced prostate cancerOligometastases from prostate cancer: local treatment with stereotactic body radiotherapy (SBRT)Improved survival with the addition of radiotherapy to androgen deprivation: questions answered and a review of current controversies in radiotherapy for non-metastatic prostate cancer.Solitary recurrence of castration-resistant prostate cancer with low or undetectable levels of prostate specific antigen salvaged with local ablative radiation therapy: A case report.Overview of randomized controlled treatment trials for clinically localized prostate cancer: implications for active surveillance and the United States preventative task force report on screening?Androgen-deprivation therapy alone versus combined with radiation therapy or chemotherapy for nonlocalized prostate cancer: a systematic review and meta-analysis
P2860
Q26739738-C6A5198F-9AE5-451C-B95B-390BDEACB70AQ26744606-68F6081B-073A-4B74-AF13-1E742DA3586FQ26766638-271C22B5-783E-4421-ACDF-85546E58D92BQ26767456-9A71E3C0-C2E3-4AF9-B7B2-CC6DDA3A87AFQ26801000-63B21D1F-AD5B-4E92-A4BD-CC3C274654BDQ26801188-51CB6BD9-3F38-434B-931F-7162B87462DAQ26852751-C9D5DCB9-9DC5-4CA7-BC23-8FA51E7AE6D8Q26865377-EC4F70C2-9C4A-4EFE-B714-15264DA92252Q26866565-13B25E9E-8E7C-4C04-9F03-10F73BDA2BBBQ27000180-743B05EE-1FC9-4F8A-B892-CC6E5C4F16D1Q27022847-95CF8ADE-BBB0-45EC-829A-8F5D95B33D8EQ28262606-D80604C3-3312-432E-93E0-D93144BAC4BBQ28550301-34E72358-FE48-4821-A50B-3B5DC5C1030EQ30521133-E65C4E8E-F1D2-490D-BD7D-F9622038FBE9Q31028126-DF4075E0-827C-4723-A9F4-C411201460EFQ34245541-056B708F-9C70-43CA-B3C2-B2B45D57C278Q34315605-C9E56390-C1AB-4B67-B976-0DAEDC00ECFEQ34987693-BA9FEAA7-F188-4468-88B2-BDD985A5990DQ35102488-2A987492-88BD-4179-A0D1-B16983C873DDQ35151890-3007C780-E451-4D68-90C4-AA3C936DD2ABQ35605711-E08F8039-3675-4DD7-9737-430851A1C524Q35663315-DF80722C-0BAD-4AAA-B20B-6D3A8ED49D61Q35684054-CE6D1BC9-0DCE-4F07-9AB6-37A596DE25FCQ35771166-CF8BEAAE-E3AA-4492-928D-466F5912DAB1Q35771173-6F1B4DA7-F675-44FA-9FF9-A9BA8E161208Q35803832-190DEBD4-77FE-4A51-93DE-1C5F59D3B428Q35869811-EF5500ED-4641-4B26-A279-F03A5C9B8247Q35912658-A6D77E12-930F-4151-BC1C-D14662EC4153Q36119749-A4FCC668-4E60-492F-9CF5-F3469754488FQ36199134-F879061F-4443-47F5-87FC-95705DD18B4CQ36241918-20F0A6A0-BDB0-4001-8E6B-81690FB09AF3Q36293177-1C4C1E29-8FBC-4CB2-BE42-97554344EFB9Q36303184-3CCF25AD-2B2E-41EC-8446-1F902D5DBF7BQ36338835-2AC5B180-1937-4F74-97FD-B4DEEB799D8FQ36348825-0FBD1FFE-09CF-4FA8-8F17-E94401F1EA72Q36377961-6DF35AFC-EBE6-4034-B4F8-9323A995406AQ36474222-1C63FC3C-78C1-4F07-82A1-B87E88A39E16Q36502875-65AFA0AA-9D2E-44E3-B139-67B06E7ADD42Q36520539-24073CBD-6042-477F-8A3B-7AFEE06BFA5CQ36530173-11C58880-E17F-43F4-B043-D9F516EEC36D
P2860
Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Combined androgen deprivation ...... : a randomised, phase 3 trial.
@ast
Combined androgen deprivation ...... : a randomised, phase 3 trial.
@en
type
label
Combined androgen deprivation ...... : a randomised, phase 3 trial.
@ast
Combined androgen deprivation ...... : a randomised, phase 3 trial.
@en
prefLabel
Combined androgen deprivation ...... : a randomised, phase 3 trial.
@ast
Combined androgen deprivation ...... : a randomised, phase 3 trial.
@en
P2093
P2860
P50
P1433
P1476
Combined androgen deprivation ...... : a randomised, phase 3 trial.
@en
P2093
Andrea Hiltz
Charles Hayter
Edmund Kostashuk
Greg Swanson
Jim Barber
Jinka Sathya
John Anderson
John Hetherington
Karen Sanders
Keyue Ding
P2860
P304
P356
10.1016/S0140-6736(11)61095-7
P407
P577
2011-11-02T00:00:00Z